Novartis (NVS)
(Delayed Data from NYSE)
$108.13 USD
+1.35 (1.26%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $108.20 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.13 USD
+1.35 (1.26%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $108.20 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Novartis (NVS) closed at $108.03 in the latest trading session, marking a -0.21% move from the prior day.
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
by Zacks Equity Research
Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annexon, Inc. (ANNX) and Novartis (NVS) have performed compared to their sector so far this year.
Zacks Investment Ideas feature highlights: Eli Lilly and Novartis
by Zacks Equity Research
Eli Lilly and Novartis have been highlighted in this Investment Ideas article.
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
by Bryan Hayes
As investors, our job isn't to predict an unknowable future.
Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Novartis (NVS) settling at $107.45, representing a -0.14% change from its previous close.
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
by Zacks Equity Research
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.
Novartis (NVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $107.60, marking a +0.15% move from the previous day.
Bullish Continuation in '24? 3 Market Areas to Watch
by Andrew Rocco
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
by Zacks Equity Research
Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.
Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates
by Zacks Equity Research
Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.
The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group
by Zacks Equity Research
Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.
Novartis (NVS) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Novartis (NVS) closed at $106.31, indicating a +0.7% shift from the previous trading day.
Top Analyst Reports for Merck, Salesforce & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
by Zacks Equity Research
Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
by Zacks Equity Research
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
Novartis (NVS) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Novartis (NVS) stood at $101, denoting a +0.03% change from the preceding trading day.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.
Novartis (NVS) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Novartis (NVS) closed at $99.71 in the latest trading session, marking a +1.18% move from the prior day.
The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours
by Zacks Equity Research
Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours are part of the Zacks top Analyst Blog.
Novartis (NVS) Stock Moves -1.17%: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $97.14, moving -1.17% from the previous trading session.
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.